Medicare AdvantageCoverageMedium impact
MA08.190, Chimeric Antigen Receptor T-cell (CAR-T) Therapy: Carvykti® and Abecma®
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Feb 9, 2026
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA08.190 has been established for Chimeric Antigen Receptor T-cell (CAR-T) Therapy, specifically covering Carvykti® and Abecma® treatments. This policy will define coverage criteria and billing requirements for these specialized cancer immunotherapy treatments.
Action Required
Before February 9, 2026: Oncology and hematology billing teams should review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Carvykti® and Abecma® CAR-T therapies. Update billing workflows and ensure staff are trained on requirements for Medicare Advantage patients receiving these treatments.